Asking for Money Back - Chilling Commercialization or Recouping Public Trust in the Context of Stem Cell Research?

34 Pages Posted: 22 Aug 2009

See all articles by Matthew Herder

Matthew Herder

Dalhousie University - Faculties of Medicine and Law; Dalhousie University - Faculty of Medicine

Date Written: May 14, 2008

Abstract

As publicly funded institutions have increasingly embraced the goal of commercializing scientific research, concerns about private appropriation have become familiar refrain. One commonly suggested remedy is to create some kind of 'recoupment' provision whereby the State, on behalf of the public, receives a certain percentage of profits realized. The Bayh-Dole Act originally included a recoupment provision but it was deleted by a legislative committee. Countries around the globe attempting to emulate Bayh-Dole have, whether by design or default, reinforced the underlying logic against recoupment, which is essentially as follows: obligations to provide direct financial returns undermine the commercialization process and therefore threaten what the public cares about most, i.e. the production of new goods. Despite regular controversies over alleged windfalls to industry, this logic has continued to prevail — until now. The California Institute of Regenerative Medicine (CIRM) has recently issued two intellectual property policies applicable to non-profit and for-profit grant recipients respectively, each of which contains mechanisms to recoup a portion of the public’s tax dollar investment. Why? This Article aims to explore that question by: one, further explaining the curious history in which the wisdom against recoupment came to prevail; two, probing the details of CIRM’s intellectual property policies and examining the arguments for and against the recoupment formulae they establish; and three, revealing the limits of what is actually known about whether such mechanisms exert a chilling effect on the commercialization process, and whether or not a direct financial return is what the public values most. In the end, the value of recoupment may be best conceived of in democratic terms: as one means of attempting to balance a host of conflicting views, and preserving public trust as the many promises of biotechnology become increasingly integral to nation-building strategies and our lives.

Keywords: patents, intellectual property, stem cell research, recoupment, Bayh-Dole Act

Suggested Citation

Herder, Matthew, Asking for Money Back - Chilling Commercialization or Recouping Public Trust in the Context of Stem Cell Research? (May 14, 2008). Columbia Science and Technology Law Review, Vol. IX, 2008, Available at SSRN: https://ssrn.com/abstract=1458382

Matthew Herder (Contact Author)

Dalhousie University - Faculties of Medicine and Law ( email )

6225 University Avenue
Halifax, Nova Scotia B3H 4H7
Canada

Dalhousie University - Faculty of Medicine ( email )

Do you have negative results from your research you’d like to share?

Paper statistics

Downloads
113
Abstract Views
964
Rank
438,854
PlumX Metrics